Article Text

other Versions

PDF
A randomized cross-over study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma
  1. Alicia C How,
  2. Rajesh S Kumar,
  3. Yu-Ming Chen,
  4. Daniel H Su,
  5. Hong Gao,
  6. Francis T Oen,
  7. Ching-Lin Ho,
  8. Steve K Seah,
  9. Tin Aung (tin11{at}pacific.net.sg)
  1. Singapore National Eye Centre, Singapore
  2. Singapore National Eye Centre, Singapore
  3. Clinical Trials and Epidemiology Research Unit, Singapore, Singapore
  4. Singapore National Eye Centre, Singapore
  5. Clinical Trials and Epidemiology Research Unit, Singapore, Singapore
  6. Singapore National Eye Centre, Singapore
  7. Singapore National Eye Centre, Singapore
  8. Singapore National Eye Centre, Singapore
  9. Singapore National Eye Centre, Singapore

    Abstract

    Background/aims: To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).

    Methods: This was an observer-masked randomized cross-over study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared to baseline.

    Results: Fifty-four subjects (80 eyes) completed the study. Latanoprost reduced IOP (mean ± SD) by 8.4 ± 3.8 mmHg and bimatoprost by 8.9 ± 3.9 mmHg from a baseline of 25.2 + 3.6 mmHg and 25.2 + 3.6 mmHg respectively (p=0.23). Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared to the latanoprost group (40%, p<0.01). Ocular irritation was the most frequently reported adverse events in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperemia as compared to 13 subjects (22.4%) treated with latanoprost (p=0.11).

    Conclusions: Bimatoprost once daily was similarly effective in reducing IOP compared to latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • At a glance
      Harminder S Dua Arun D Singh